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Abstract
Background: With advances in gastric cancer chemotherapy, conversion surgery has drawn attention as a new
strategy to improve the outcome of stage IV disease. We investigated the efficacy of conversion surgery following
chemotherapy for patients with stage IV gastric cancer.
Methods: We retrospectively reviewed clinico-pathologic variables and oncologic outcomes for 101 patients with
stage IV gastric cancer who were treated with systemic chemotherapy followed by gastrectomy with intension of
curative resection from January 2005 to December 2012.
Results: In terms of the best response from palliative chemotherapy, complete or partial response were observed
in 65 patients (64.4%) in overall. Complete response of metastatic site were observed in 72 (71.3%) and 66 (65.3%)
patients as best and pre-operative response, respectively. The overall complete macroscopic resection, rate was
56.4%. Eleven patients (10.9%) received combined metastasectomy. There was no postoperative surgery-related
mortality for 1 month. The median overall survival time was 26.0 months. Multivariable analysis identified complete
macroscopic resection, chemotherapy response (complete response/partial response) of metastatic sites, and
change in CEA level as independent prognostic factors contributing to overall survival.
Conclusions: Patients with stage IV gastric cancer who exhibit a good clinical response to chemotherapy might
obtain greater survival benefit from gastrectomy following chemotherapy compared with patients who exhibit a poor
response to chemotherapy. Prospective, randomized trials are required to determine the best strategy for combining
initial chemotherapy with subsequent gastrectomy.
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Background
Despite a declining incidence in many developed countries,
gastric cancer remains the second most common cause of
cancer-related deaths in the world [1, 2]. Although the
prognosis of metastatic gastric cancer is poor, combination
chemotherapy improved the quality of life and overall
survival (OS) compared with the best supportive care in
several randomized studies [3, 4]. In general, 5-fluorouracil
(5-FU)-based or cisplatin-based combination regimens are
widely accepted as potential standard therapies with a
response rate of around 30–40% and median OS of 9–
11 months [5, 6]. More recently, even greater progress has
been achieved by combining conventional chemotherapy
with a targeted monoclonal antibody (median OS,
13.8 months) [7]. Although a large proportion of patients
with metastatic or recurrent gastric cancer respond initially
to chemotherapy, the disease ultimately progresses. In
addition, a substantial proportion of patients have primary
refractory diseases. Therefore, novel therapeutic strategies
for treating metastatic gastric cancer are required.
Currently, surgery is not a standard treatment option for
patients with gastric cancer with distant metastasis, except
for those who need palliative surgery for bleeding,
obstruction, or perforation caused by the tumor. Recently,
a randomized, controlled trial of reduction surgery plus
chemotherapy versus chemotherapy alone for M1 gastric
cancer (REGATTA trial) failed to show any efficacy of sur-
gery [8]. Recent advances in chemotherapy for gastric can-
cer have raised new clinical questions regarding the role of
surgical intervention for patients with a good chemother-
apy response, even if the patients have distant metastasis.
Surgery for those patients might provide long-term survival
benefit by removing macroscopic lesions remaining after
chemotherapy. That type of surgery, referred to as conver-
sion surgery, aims to cure the disease, rather than just pro-
vide palliative treatment, on the basis of the response to
chemotherapy, as is done for initially unresectable colorec-
tal cancer [9]. However, the clinical value of such multi-
modal therapy combining chemotherapy and conversion
surgery for stage IV gastric cancer remains controversial.
The aim of this study was to evaluate the efficacy and
feasibility of surgery in patients with stage IV gastric
cancer who were treated by gastrectomy following
chemotherapy, with a particular focus on the selection
of patients who might benefit from conversion surgery.
Methods
Patients
We retrospectively identified patients with a clinical diag-
nosis of stage IV gastric cancer who underwent gastrec-
tomy following chemotherapy in Yonsei Cancer Center
from January 2005 through December 2012. The key eligi-
bility criteria were: (i) patients with histologically proven
gastric cancer, (ii) who received systemic chemotherapy at
the time of diagnosis of stage IV disease according to the
AJCC 7th staging system, and (iii) underwent subsequent
gastrectomy with the intention of curative resection.
Consecutive patients corresponding to those criteria were
included. We initially identified 106 patients who under-
went gastrectomy following chemotherapy. Four patients
were excluded because the aim of surgery was palliative
(two patients underwent gastrectomy because of bleeding,
and two patients did so because of gastric obstruction).
One additional patient who received initial chemotherapy
at another institution was excluded from the analysis,
because there were no available clinical data from the time
of diagnosis. Thus, we analyzed 101 patients (Add-
itional file 1: Figure S1). This study was approved by the
Institutional Review Board of Severance Hospital, Yonsei
University College of Medicine (4–2016-0408).
Variables for analyses
We grouped the variables collected for study into four
categories: baseline characteristics, chemotherapy-related
information, variables before operation, and surgical out-
comes including pathologic results. The baseline character-
istics included age, gender, clinical T and N stage, type of
distant metastasis, neutrophil / lymphocyte ratio (NLR, %),
systemic immune-inflammation index (SII, platelet count ×
neutrophil count / lymphocyte count), and albumin level
(g/dL) at initial diagnosis. The chemotherapy-related infor-
mation included the regimen of palliative chemotherapy;
the best response and preoperative response (response at
the time before operation) to palliative chemotherapy over-
all, at the local region, and at the metastatic sites; number
of cycles of chemotherapy. The response to chemotherapy
was defined according to RECIST criteria version 1.1 and
categorized as complete response (CR), partial response
(PR), stable disease (SD), or progressive disease (PD) [10].
The variables before operation included the change in body
mass index (BMI), the change in tumor markers, the clin-
ical T and N stage immediately prior to surgery, and during
the time interval between the initial diagnosis and surgery.
Clinical T and N stage was evaluated by one radiologist
with CT images according to AJCC 7th guideline. We as-
sumed stomach lesion with definite extramural fat infiltra-
tion or adjacent organ invasion as clinical T4 lesion. The
patients were classified into three categories based on BMI
(kg/m2) in the period between diagnosis and surgery:
underweight (BMI < 17.5), overweight (BMI ≥ 23.0), and
normal (17.5 ≤ BMI < 23.0). The changes in the carcinoem-
bryonic antigen (CEA) and carbohydrate antigen (CA 19–
9) tumor markers between the initial diagnosis and surgery
were classified as stable (no change), improved (high levels
decreased to the normal range), worse (normal levels
increased to the high range), and not available (with any
missing value). The surgical outcomes included the
presence of peritoneal infiltration, whether or not
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metastasectomy was performed, the extent of gastrectomy
and lymph node (LN) dissection, and curative resection. In
this study, curative resection means complete macroscopic
resection (CMR) which was defined there was no visible
tumor in abdomen after surgery. We also considered vari-
ables of the pathologic T and N stage, the Lauren classifica-
tion of the surgical specimen, and presence of
postoperative chemotherapy as potential prognostic factors.
Statistical analysis
We analyzed categorical variables based on the propor-
tions among the patients and continuous variables based
on the mean and standard deviation. The primary out-
come was OS, defined as the time from the diagnosis of
gastric cancer to the time of death by any cause. We
generated survival curves by the Kaplan-Meier method
and compared them by log-rank tests. We used a Cox
proportional hazard regression model to identify risk
factors for OS. We described the risk factors by a hazard
ratio (HR) with 95% confidence interval (CI). We con-
ducted a multivariable Cox analysis with the variables
that had p-value ≤0.10 in the univariable analyses. We
selected the final model by the forward likelihood ratio
method. Two-tailed p-value ≤0.05 was considered statis-
tically significant. All analyses were conducted using
SPSS (version 19.0 software, IBM SPSS, Chicago, IL).
Results
Characteristics of the patients
The median age of the enrolled patients was 52 years
(Table 1). The study population was 59.4% male. At the
time of diagnosis, 80.2% of the patients were suspected to
have clinically serosa-positive depth of invasion, and 84.2%
of the patients were suspected to be beyond the clinical N1
stage. The reasons for diagnosis of stage IV disease varied,
including peritoneal carcinomatosis (32.7%), liver metasta-
sis (10.9%), distant LN metastasis (34.7%), Krukenberg
tumor (20.0%), and two or more distant metastases
(19.8%). The mean baseline values of NLR, SII, and
albumin were 2.67, 9.14, and 3.94, respectively.
The preoperative chemotherapy regimen was platinum
plus fluoropyrimidine in 50.5% of the patients, taxane
plus fluoropyrimidine in 11.9% of the patients, platinum
plus taxane plus fluoropyrimidine in 14.9% of the pa-
tients, taxane plus platinum in 15.8% of the patients,
and others in 6.9% of the patients. Overall, 64.4 and
59.4% of the patients had CR or PR to preoperative
chemotherapy as best response and preoperative re-
sponse to the chemotherapy, respectively. When the re-
sponses were divided into the local region and the
metastatic sites, the rate of CR/PR was lower in the local
region (46.5 and 42.6%) than in the metastatic sites (83.2
and 77.2%) in both best response and preoperative re-
sponse. CR of metastatic site was observed in 72 (71.3%)
and 66 (65.3%) patients in best and preoperative re-
sponse, respectively. The median number of cycles of
chemotherapy was 6 (1–32 cycles).
Nine patients (8.9%) were considered underweight dur-
ing chemotherapy treatment, and 52.5% of the patients
were considered overweight. The levels of CEA and
CA19–9 improved in 16 and 10 patients, respectively, and
worsened in 3 and 5 patients, respectively. After the initial
chemotherapy, both the T and the N staging was down-
graded in overall; the proportion of serosa-negative was
47.5% and that of N0/N1 was 32.7%. The interval from
chemotherapy to surgery was ≤24 weeks in 51 patients.
During the surgery, 32 patients displayed peritoneal in-
filtration. Metastasectomy was conducted for 11 patients
(three hepatectomy, six para-aortic LN dissection, and
three oophorectomy). Fifty-seven patients underwent total
gastrectomy, and 76 patients underwent ≥ D2 LN dissec-
tion. Finally, CMR was achieved in 57 patients (56.4%),
and 46 and 42 patients were found to have intestinal and
diffuse-type gastric cancer, respectively. In the final patho-
logic diagnosis, 54 (53.5%) of the patients were serosa
positive (pT4a/b), and 66 of the patients (65.3%) had ≥3
metastatic LNs. Eighty-four patients were treated with
postoperative chemotherapy. There was no postoperative
surgery-related mortality for 1 month. The detailed infor-
mation is summarized in Table 1.
Prognostic factors in the population
The median follow-up duration was 63.3 months.
Seventy-three patients (72.3%) died during follow up. The
median OS of the patients was 26.0 (95% CI, 21.6–30.3)
months. Figure 1a depicts the different prognoses by the
type of distant metastasis. Compared with the prognoses
for patients with other types of distant metastasis, the
prognosis for patients with liver metastasis (median
survival, 49.2 months) was better, and that for patients
with Krukenberg tumor (median survival, 13.6 months)
was worse. In the univariate Cox analyses, greater age was
related to better OS (p = 0.047), whereas other baseline
characteristics such as gender, initial clinical T and N
stage, and initial NLR, SII, and albumin levels were not
statistically significant (Table 2).
There was no difference in prognosis based on the regi-
men of preoperative chemotherapy (Fig. 1b and Table 2).
The overall response to chemotherapy was not statistically
significant to the prognosis in both best and preoperative
response (log-rank p = 0.199, 0.634, respectively, Fig. 2a
and d). The response of local region to chemotherapy
showed similar prognosis in both best and preoperative
response (log-rank p = 0.575, 0.875, respectively, Fig. 2b
and e). However, CR/PR at the metastatic sites was signifi-
cantly related to OS in both best and preoperative response
(log-rank p = 0.011 and 0.018, respectively, Fig. 2c and f)
and univariate HRs were also statistically significant (HR
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for best response: 2.105 [1.171–3.783], p = 0.013, HR for
preoperative response: 1.850 [1.103–3.103], p = 0.020,
Table 2).
Among the preoperative variables, BMI and changed
CEA level was related to prognosis (Fig. 3a and b, and
Table 2): patients experienced underweight were related
Table 1 Characteristics of the enrolled patients (n = 101)
Baseline Characteristics Chemotherapy Preoperative Surgical Outcomes
Age, median,
years
52 (range 26–78) Regimen BMI Peritoneal infiltration
Gender Platinum + FU 51 (50.5) Normal 39 (38.6) No 69 (68.3)
Male 60 (59.4) Taxane + FU 12 (11.9) Under weight 9 (8.9) Yes 32 (31.7)
Female 41 (40.6) Platinum + Taxane + FU 15 (14.9) Over weight 53 (52.5) Metastasectomy
cT stage Taxane + Platinum 16 (15.8) Change of CEA level No 90 (89.1)
Serosa
negative
20 (19.8) Others 7 (6.9) Stable 66 (65.3) Yes 11 (10.9)
Serosa positive 81 (80.2) Best response Improved 16 (15.8) Hepatectomy 3
cN stage Overall Worse 3 (3.0) #16 6
N0/N1 16 (15.8) CR/PR 65 (64.4) NA 16 (15.8) Oophorectomy 3
N2/N3 85 (84.2) SD/PD 36 (35.6) Change of CA19–9 level Extent of gastrectomy
Type of distant metastasis Local region Stable 66 (65.3) TG 57 (56.4)
Peritoneal
carcinomatosis
33 (32.7) CR/PR 47 (46.5) Improved 10 (9.9) DG 44 (43.6)
Liver
metastasis
11 (10.9) SD/PD 54 (53.5) Worse 5 (5.0) Extent of LND
Distant LN
metastasis
35 (34.7) Metastatic site NA 20 (19.8) < D2 25 (24.8)
Krukenberg
tumor
2 (2.0) CR/PR 84 (83.2) Pre_op cT stage ≥ D2 76 (75.2)
Any
combination
20 (19.8) SD/PD 17 (16.8) Serosa negative 48 (47.5) Complete macroscopic resection
NLR (Neut/
lympho)
2.67 ± 1.30 Preoperative response Serosa positive 53 (52.5) Yes 57 (56.4)
SII (PLT*Neut/
lympho)
9.14 ± 6.88 Overall Pre_op cN stage No 44 (43.6)
Albumin (g/dL) 3.94 ± 0.53 CR/PR 60 (59.4) N0/N1 33 (32.7) pT stage
SD/PD 41 (40.6) N2/N3 68 (67.3)
Serosa negative (pT1–3)
47 (46.5)
Local region Interval to surgery
Serosa positive (pT4a/b)
54 (53.5)
CR/PR 43 (42.6) ≤ 24 weeks 51 (50.5) pN stage
SD/PD 58 (57.4) > 24 weeks 50 (49.5) pN0/N1 35 (34.7)
Metastatic site pN2/N3 66 (65.3)
CR/PR 78 (77.2) Lauren classification
SD/PD 23 (22.8) Intestinal 46 (45.5)
Number of Cycles
of Chemotherapy
6 (range 1–32) Diffuse 42 (41.6)
≤ 6 cycles 62 (61.4) Others 13 (12.9)
> 6 cycles 39 (38.6) Postoperative chemotherapy
No 17 (16.8)
Yes 84 (83.2)
LN lymph node, NLR neutrophil lymphocyte ratio, SII systematic immune-inflammation index, CR complete response, PR partial response, SD stable disease, PD
progressive disease, BMI body mass index, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, TG total gastrectomy, DG distal gastrectomy, LND
lymph node dissection, FU fluoropyrimidine
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to poor prognosis (p = 0.002) and patients with improved
CEA level were related good prognosis (p = 0.003). Other
variables such as changed CA19–9 level, preoperative
clinical T and N stage, and interval to surgery were not
related to the prognosis (Fig. 3c-f and Table 2).
Figure 4 and Table 2 showed the prognosis of each
variable of surgical outcomes. The presence of peritoneal
infiltration (p = 0.001, Fig. 4a), extent of gastrectomy
(p = 0.007, Fig. 4b), CMR (p < 0.001, Fig. 4d), pathologic T
stage (p = 0.002, Fig. 4f), Lauren classification (p = 0.001,
Fig. 4e) were related to the prognosis, and univariable Cox
analysis showed similar results (Table 2). Other factors
such as metastasectomy, extent of LN dissection, patho-
logic N stage, and postoperative chemotherapy were not
related to OS (Fig. 4c, g, h and Table 2).
The multivariable analysis was conducted with the vari-
ables that had p-value < 0.1 in the univariate analyses (age,
type of distant metastasis, best response of the metastatic
sites, BMI, change in CEA level, preoperative cT stage,
presence of peritoneal infiltration, extent of gastrectomy,
CMR, pT stage, and Lauren classification). The best
response of the metastatic sites [HR: 1.822 (0.999–3.323),
p = 0.050], change in CEA level [HR of improved, worse,
and NA compared with stable: 0.564 (0.259–1.226), p =
0.148; 5.013 (1.477–17.017), p = 0.010; 0.973 (0.504–
1.877), p = 0.935; respectively; overall p = 0.024], and CMR
[HR: 1.998 (1.233–3.238), p = 0.005] were selected as fac-
tors that related to the prognosis of the patients (Table 3).
Subgroup analyses by the type of distant metastasis
Subgroup analyses according to the type of distant me-
tastasis were conducted to evaluate the effects of the
variables that were selected for the final model (best
response of metastatic sites, change in CEA level, and
CMR). In the patients with peritoneal carcinomatosis,
there was no trend for the best response of metastatic
sites or change in CEA level (Additional file 2: Figure
S2A and B), and CMR was marginally related to better
survival but was not statistically significant (log-rank p =
0.064, Additional file 2: Figure S2C). There were no re-
markable trends among the patients with liver metastasis
(Additional file 3: Figure S3A-C) and distant LN metas-
tasis (Additional file 4: Figure S4A-C), respectively.
Among the patients with two or more distant metasta-
ses, the best response of the metastatic sites was related
to OS (log-rank p = 0.007, Additional file 5: Figure S5A),
and there were trends for better prognosis with im-
proved CEA level and CMR, respectively, although those
trends were not statistically significant (Additional file 5:
Figure S5B and C).
Discussion
Patients with stage IV gastric cancer usually have a poor
prognosis and are primarily considered for systemic
chemotherapy, but not for surgery. The exception to that
is patients who require rapid palliation of cancer-related
complications such as bleeding or obstruction [11]. Re-
cent advances in gastric-cancer chemotherapy, including
the introduction of new anticancer agents and the devel-
opment of multi-agent regimens, have made complete
macroscopic resection possible in some patients with
stage IV gastric cancer. That strategy of treatment is re-
ferred to as conversion gastrectomy with curative intent
and is distinct from palliative gastrectomy. The results
Fig. 1 Kaplan-Meier curves with log-rank test for overall survival of the patients with stage IV gastric cancer who treated by gastrectomy
following chemotherapy a) according to the type of distant metastasis, b) and chemotherapy regimen
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Table 2 Univariate Cox proportional hazard model of overall survival by each variable
Baseline Characteristics HR (95% CI) p-value Chemotherapy HR (95% CI) p-value
Age 0.978 (0.958–1.000) 0.047 Regimen 0.941
Gender 0.111 Platinum + FU 1
Male 1 Taxane + FU 1.336 (0.643–2.776) 0.437
Female 1.464 (0.916–2.339) Platinum + Taxane + FU 1.116 (0.569–2.188) 0.750
cT stage 0.734 Taxane + Platinum 1.003 (0.511–1.969) 0.994
Serosa negative 1 Others 0.904 (0.354–2.306) 0.832
Serosa positive 1.107 (0.616–1.988) Best response
cN stage 0.743 Overall 0.201
N0/N1 1 CR/PR 1
N2/N3 1.109 (0.597–2.061) SD/PD 1.359 (0.849–2.175)
Type of distant metastasis 0.065 Local region 0.576
Peritoneal carcinomatosis 1 CR/PR 1
Liver metastasis 0.407 (0.166–0.994) 0.049 SD/PD 1.142 (0.717–1.817)
Distant LN metastasis 1.025 (0.590–1.780) 0.930 Metastatic site 0.013
Krukenberg tumor 4.423 (1.004–19.487) 0.049 CR/PR 1
Any combination 0.900 (0.467–1.735) 0.753 SD/PD 2.105 (1.171–3.783)
NLR (Neut/lympho) 1.349 (0.837–2.177) 0.219 Preop. response
SII (PLT*Neut/lympho) 1.252 (0.776–2.019) 0.357 Overall 0.635
Albumin 0.986 CR/PR 1
low 1 SD/PD 1.119 (0.704–1.777)
normal 1.006 (0.480–2.108) Local region 0.875
CR/PR 1
SD/PD 0.963 (0.602–1.540)
Metastatic site 0.020
CR/PR 1
SD/PD 1.850 (1.103–3.103)
Number of Cycles of Chemotherapy 0.970 (0.930–1.013) 0.167
≤ 6 cycles 1 0.746
> 6 cycles 0.925 (0.578–1.480)
Pre-Operation HR (95% CI) p-value Surgical Outcomes HR (95% CI) p-value
BMI 0.004 Peritoneal infiltration 0.002
Normal 1 No 1
Underweight 3.538 (1.607–7.789) 0.002 Yes 2.181 (1.343–3.540)
Overweight & obese 1.073 (0.647–1.778) 0.786 Metastasectomy 0.252
Change in CEA level 0.009 No 1
Stable 1 Yes 1.507 (0.747–3.039)
Improved 0.410 (0.193–0.868) 0.020 Extent of gastrectomy 0.008
Worse 4.174 (1.255–13.881) 0.020 TG 1
NA 0.856 (0.446–1.646) 0.642 DG 0.521 (0.322–0.842)
Change in CA19–9 level 0.399 Extent of LND 0.402
Stable 1 < D2 1
Improved 1.020 (0.437–2.381) 0.963 ≥ D2 0.802 (0.480–1.343)
Worse 0.907 (0.282–2.911) 0.869 Complete Macroscopic Resection < 0.001
NA 0.580 (0.309–1.089) 0.090 Yes 1
Beom et al. BMC Cancer         (2018) 18:1116 Page 6 of 12
Table 2 Univariate Cox proportional hazard model of overall survival by each variable (Continued)
Baseline Characteristics HR (95% CI) p-value Chemotherapy HR (95% CI) p-value
Pre_op cT stage 0.069 No 2.348 (1.471–3.748)
Serosa negative 1 pT stage 0.002
Serosa positive 1.537 (0.967–2.444) Serosa negative (pT1–3) 1
Pre_op cN stage 0.567 Serosa positive (pT4a/b) 2.109 (1.311–3.393)
N0/N1 1 pN stage 0.121
N2/N3 1.155 (0.705–1.894) pN0/N1 1
Time interval to surgery 0.926 pN2/N3 1.480 (0.901–2.430)
≤ 24 weeks 1 Lauren classification 0.013
> 24 weeks 0.926 (0.584–1.468) Intestinal 1
Diffuse 1.960 (1.204–3.190) 0.007
Others 0.867 (0.361–2.079) 0.748
Postoperative chemotherapy 0.172
No 1
Yes 1.629 (0.809–3.281)
LN lymph node, NLR neutrophil lymphocyte ratio, SII systematic immune-inflammation index, CR complete response, PR partial response, SD stable disease, PD
progressive disease, BMI body mass index, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, TG total gastrectomy, DG distal gastrectomy, LND
lymph node dissection, FU fluoropyrimidine
The bold represents statistical significance
Fig. 2 Kaplan-Meier curves with log-rank test for overall survival of the patients with stage IV gastric cancer who treated by gastrectomy
following chemotherapy a) by overall response in best response of chemotherapy, b) by chemotherapy response of local region, c) by
chemotherapy response of metastatic site, d) by overall response before operation, e) by response of local region before operation, f) by
response of metastatic site before operation
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Fig. 3 Kaplan-Meier curves with log-rank test for overall survival of the patients with stage IV gastric cancer who treated by gastrectomy
following chemotherapy a) by BMI, b) by change of CEA level, c) by change of CA19–9 level, d) pre-operative clinical T stage, e) by pre-operative
N stage, f) by time interval between diagnosis and surgery
Fig. 4 Kaplan-Meier curves with log-rank test for overall survival of the patients with stage IV gastric cancer who treated by gastrectomy
following chemotherapy a) by the presence of peritoneal infiltration, b) by extent of gastrecotmy, c) by extent of lymph node dissection,
d) by complete macroscopic resection or not, e) by Lauren classification, f) by pathologic T stage, g) by pathologic N stage, h) by post-
operative chemotherapy or not
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of previous studies of surgical resection after preoperative
chemotherapy for initially metastatic gastric cancer are
summarized in Table 4 [12–24]. Although the chemother-
apy regimens and definitions of gastrectomy varied across
the studies, the reported OS ranged 19 to 53 months,
which revealed much better outcomes, considering the
generally poor prognosis for stage IV gastric cancer. The
limitations of the previous studies include small study
samples and the use of retrospective methods of analysis.
Some of the studies investigated prognostic factors for
gastrectomy and presented various factors including R0
resection as significant prognostic factors.
In our study, the median OS of the patients was
26.0 months. Survival outcomes did not differ significantly
according to clinical factors at diagnosis including meta-
static sites and chemotherapy regimens. In addition to
CMR, CEA change as well as the response of metastatic
sites to chemotherapy were significant prognostic factors
in the multivariable analysis.
Successful curative surgical resection is the most fre-
quently presented prognostic factor of conversion gastrec-
tomy so far. Yabusaki et al. reported that patients obtaining
CR/PR to chemotherapy as well as those with R0 resection
and D2/D3 LN dissection had longer survival [21]. Fukuchi
et al. also demonstrated that R0 resection as well as one
non-curative factor was an independent significant
predictor for overall survival in patients who underwent
conversion surgery [22]. In general, R0 resection which
means that no cancerous cell is seen microscopically in
surgical specimen corresponds to resection for cure or
complete remission. However, definitive R0 resection is
rarely achieved because many cases with stage IV gastric
cancer have non-measurable lesions including peritoneal
diseases. For example, peritonectomy or pathologic con-
firmation of residual cancer in surgery for this case is not
common surgical procedure in operative field. Our data
showed that only 11(10.9%) of 101 patients underwent
metastasectomy with gastrectomy. Thus we defined that
curative resection means complete macroscopic resection
in abdomen after surgery. Definition of the concept of
“conversion therapy” and the patients who are eligible for
such a procedure remain to be clarified.
In this study, the response to chemotherapy was import-
ant to the prognosis following surgery. Our data showed
that the response of the metastatic sites, rather than the
overall response, to chemotherapy was a significant prog-
nostic factor. The reason could be related to the original
nature of the RECIST evaluation system. We analyzed the
chemotherapy response by dividing the response into that
of the local region and that of the metastatic sites, adding
those responses to the overall tumor response. The local
tumor, including the primary stomach cancer and the re-
gional LNs, is mostly evaluated as a non-measurable le-
sion, and its response is categorized as CR, non-CR/
non-PD, or PD. CR of the primary stomach cancer is sel-
dom observed. For example, although metastatic sites
without measurable lesion reveal CR, the overall response
is not CR or PR but is instead non-CR/non-PD in cases in
which the local tumor without measurable lesion showed
a non-CR/non-PD response. Our results suggest that the
chemotherapy response of the metastatic sites is more im-
portant than the overall response for the selection of pa-
tients who would benefit from conversion gastrectomy.
Our results demonstrate that, in addition to the tumor
response assessed grossly, the biochemical tumor response
is another significant prognostic factor for OS. Patients
with an improved CEA level might obtain a survival bene-
fit from curative surgery subsequent to chemotherapy. In
terms of the optimal timing of the surgery, we investigated
whether the time interval between chemotherapy and sur-
gery could influence the overall outcome, but the timing
was not significant in a univariate analysis.
Recently, the REGATTA trial demonstrated that chemo-
therapy following palliative surgery for stage IV gastric
cancer is not beneficial to survival outcomes based on an
interim analysis and the trial was early closed [8]. Surgical
resection following chemotherapy has since drawn atten-
tion from clinicians who treat patients with gastric cancer
to enhance survival. It remains unclear whether conver-
sion gastrectomy improves the prognosis in initially stage
IV gastric cancer. The results of our large-scale study
combined with those of previous studies demonstrate that
conversion surgery after preoperative chemotherapy
greatly extended survival for patients with stage IV gastric
cancer. Patients who received CMR, showed CR/PR of
metastatic sites to chemotherapy, and had an improved
CEA level during preoperative treatment could have
Table 3 Multivariable Cox proportional hazard model of overall
survival
Variablesa HR (95% CI) p-value
Best response of metastatic site 0.050
CR/PR 1
SD/PD 1.822 (0.999–3.323)
Change of CEA level 0.024
Stable 1
Improved 0.564 (0.259–1.226) 0.148
Worse 5.013 (1.477–17.017) 0.010
NA 0.973 (0.504–1.877) 0.935
Complete Macroscopic Resection 0.005
Yes 1
No 1.998 (1.233–3.238)
CR complete response, PR partial response, SD stable disease, PD progressive
disease, CEA carcinoembryonic antigen
athe final model was selected by a forward likelihood ratio method from the
variables with p-value < 0.10 in a univariate Cox proportional hazard model
The bold represents statistical significance
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considerably better prognosis than those without those
factors, suggesting that those factors might be useful selec-
tion criteria for conversion surgery. Further investigation
is required, however, to determine how to maximize the
chemotherapy response.
Our study has some limitations. First, we used a retro-
spective design to study patients at a single institute. Be-
cause of the retrospective design, the preoperative
chemotherapy regimen and the timing of the operation
varied somewhat. Second, the patients included in our
Table 4 Summary the results of gastrectomy following systemic chemotherapy for stage IV gastric cancer
Reference Author Year Metastasis Regimen of
chemotherapy
Patients who
underwent
gastrectomy
Whole study population
(if it included non-surgery
cases)
Prognostic
factors
Number
of patients
MST
(months)
Number of
patients
MST
(months)
12 Nakajima et al. 1997 M1 FLEP (5-Fluorouracil,
Leucovorin, Cisplatin,
Etoposide)
19 NA 30 6.5 NA
13 Yano et al. 2002 unresectable
(M0 + M1)
FEMTXP (5-Fluorouracil,
Epirubicin, Methotrexate,
Cisplatin) or THP-FLPM
(Pirarubicin,5-Fluorouracil,
Leucovorin, Cisplatin,
Mitomycin C)
14 NA 33 NA salvage surgery
14 Satoh et al. 2006 M0 +M1 S-1, Cisplatin 36 NA 45 21.8 NA
15 Ishigami et al. 2008 M1 Paclitaxel, S-1 18 25.7 – – R0 resection
16 Okabe et al. 2009 M1
(peritoneal
metastasis)
S-1, Cisplatin 32 NA 41 20.4 NA
17 Suzuki et al. 2010 unresectable
(M0 + M1)
Docetaxel, S-1 20 28.5 – – NA
18 Kanda et al. 2012 M1 S-1 based chemotherapy 28 29.0 – – histological
tumor length
(< 5 cm vs. ≥
5 cm)
19 Satoh et al. 2012 M1 S-1, Cisplatin 44 NA 51 19.2 NA
20 Han et al. 2013 M1 Various 34 22.9 (R0
resection)
and 7.8
(non-R0
resection)
– – ypN stage
(N0–2 vs. N3)
21 Yabusaki et al. 2013 M1 S-1, Cisplatin 97 22.5 148 16.8 surgery, R0
resection,
D2/D3 lymph
node dissection,
CR/PR response
22 Fukuchi et al. 2015 unresectable
(M0 + M1)
S-1, Cisplatin or
S-1, Paclitaxel
40 53.0 151 16.0 one non-
curative factor,
R0 resection
23 Kinoshita et al. 2015 M1 Docetaxel, Cisplatin, S-1 34 29.9 57 20.9 potential
resectability
24 Ito et al. 2015 M1 Various 14 24.8 70 14.1 NA
Present study M1 Various 101 26.0 – – curative
resection
(complete
macroscopic
resection),
chemotherapy
response
(CR/PR) of
metastatic site,
change of CEA
level
MST median survival time, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available, CEA carcinoembryonic antigen
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study did not represent the whole population of patients
with stage IV gastric cancer. Many of the patients who re-
ceived surgery were likely to have potentially resectable
disease at the time of diagnosis, and there might have
been a selection bias for patients who respond well to
chemotherapy. In addition, only small percent of patients
could be received surgery among overall patients with
stage IV gastric cancer in that period, therefore, the inter-
pretation of benefit from conversion surgery in the
present result should be cautious. Third, there might be a
discrepancy between the clinical stage and the true disease
dissemination, because metastasis was not pathologically
confirmed in most of the patients. Lastly, type II error
have to be considered for some subgroup analysis because
of small size of cohort in this study.
We evaluated the outcomes of surgery for stage IV gastric
cancer in the largest patient group to date and demon-
strated that treatment with chemotherapy followed by gas-
trectomy is feasible and improved long-term survival.
Better response (CR/PR) of metastatic sites to chemother-
apy, change of CEA level, and CMR were significant prog-
nostic factors.
Conclusion
In conclusion, although stage IV gastric cancer still
has a poor prognosis, our results suggest a practical,
multidisciplinary treatment plan for select patients.
Large-scale, prospective, multicenter, randomized tri-
als are needed to further determine the best treat-
ment strategy and to elucidate the prognostic role of
conversion gastrectomy. Numerous obstacles are yet
to be resolved regarding the selection of appropriate
patients for conversion gastrectomy, the choice of
preoperative/postoperative chemotherapy regimen for
obtaining a maximal response, and the optimal timing
of conversion surgery.
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